secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2024-01-02T23:59:59+00:00
Accession:  0001104659-24-000084
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 2.02, 3.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Therapeutics enters $100M upfront collaboration with Novartis for SMA and HD gene therapy
--------------------------------------------------------------------------------

- Voyager Therapeutics entered into a license and collaboration agreement with Novartis for AAV capsids for SMA and Huntington's disease programs, with $80M upfront payment and $20M stock purchase.
- Voyager eligible for up to $200M in milestones for SMA program and $225M for HD program, plus sales milestones and tiered royalties.
- Voyager estimates preliminary cash of $230.7M as of Dec 31, 2023; adjusted to $330.7M after anticipated $100M upfront from Novartis.
- Voyager plans to submit IND for VY-TAU01 (Alzheimer's) in first half 2024 and for SOD1 ALS gene therapy in mid-2025.
- Voyager entered into a stock purchase agreement and investor agreement with Novartis, including standstill and lock-up restrictions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465924000084/0001104659-24-000084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465924000084/tm241304d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-000084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer